Article in BioCentury: Adrecizumab shows apparent mortality benefit in septic shock trial
April 2021, by Stephen Hansen
April 2021, by Stephen Hansen
Bio€quity Europe 17–19 May, 2021 | Delivered Digitally Adrenomed will give a company presentation and and will be available for one-on-one meetings through the online partneringONE system. Speaker: Dr. Wolfgang Baiker, Chief Executive Officer. Link
BIO-Europe Spring 22–25 March, 2021 | Delivered Digitally Adrenomed will give a company presentation and and will be available for one-on-one meetings through the online partneringONE system. Speaker: Dr. Wolfgang Baiker, Chief Executive Officer Link
Adrenomed supports the #DeutschlandErkenntSepsis campaign initiated by Aktionsbündnis Patientensicherheit and supported by Sepsis Stiftung, Sepsisdialog and Deutsche Sepsis-Hilfe. The campaign’s goal is to raises awareness of sepsis and to improve recognition, diagnosis, and treatment of
Former CEO of Boehringer Ingelheim USA Corp. to accelerate Adrenomed’s development of Adrecizumab in septic shock Hennigsdorf/Berlin (Germany), January 04, 2021 – Adrenomed AG, the vascular integrity company, announced today that its Supervisory Board has
By loading the map, you agree to Google's privacy policy.
Learn more
© 2024 AdrenoMed AG | Imprint/Impressum | Legal Notice/Datenschutzerklärung | Expanded Access Policy